About: Update on the target structures of SARS-CoV-2: A systematic review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Update on the target structures of SARS-CoV-2: A systematic review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Update on the target structures of SARS-CoV-2: A systematic review
Creator	Kaur, Hardeep Sharma, Amit Avti, Pramod Bansal, Seema Bhattacharyya, Anusuya Kumar, Subodh Medhi, Bikash Prajapat, Manisha Prakash, Ajay Sarma, Phulen Shekhar, Nishant
source	Medline; PMC
abstract	Knowledge of structural details is very much essential from the drug-design perspective. In the systematic review, we systematically reviewed the structural basis of different target proteins of SARS-corona virus (CoV2) from a viral life cycle and from drug design perspective. We searched four literature (PubMed, EMBASE, NATURE, and Willey online library) databases and one structural database (RCSB.org) with appropriate keywords till April 18, and finally, 26 articles were included in the systematic review. The published literature mainly centered upon the structural details of “spike protein,” “main protease/M Pro/3CL pro,” “RNA-dependent RNA polymerase,” and “nonstructural protein 15 Endoribonuclease” of SARS-CoV-2. However, inhibitor bound structures were very less. We need better structures elucidating the interactions between different targets and their inhibitors which will help us in understanding the atomic level importance of different amino acid residues in the functionality of the target structures. To summarize, we need structures with fine resolution, co-crystallized structures with biologically validated inhibitors, and functional characterization of different target proteins. Some other routes of entry of SARS-CoV-2 are also mentioned (e.g., CD147); however, these findings are not structurally validated. This review may pave way for better understanding of SARS-CoV-2 life cycle from structural biology perspective.
has issue date	2020-06-03(xsd:dateTime)
bibo:doi	10.4103/ijp.ijp_338_20
bibo:pmid	32565603
has license	cc-by-nc-sa
schema:url	https://doi.org/10.4103/ijp.ijp_338_20
resource representing a document's title	Update on the target structures of SARS-CoV-2: A systematic review
has PubMed Central identifier	PMC7282679
has PubMed identifier	32565603
schema:publication	Indian J Pharmacol
resource representing a document's body	covid:PMC7282679#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'salt bridge' named entity 'nonstructural proteins' named entity 'SARS-CoV' named entity 'ACE2' named entity 'protein' named entity 'RdRp' named entity 'open states' named entity 'ammonium chloride' named entity 'ACE2' named entity 'SARS CoV' named entity 'RdRp' named entity 'Mpro' named entity 'HR2' named entity 'Mpro' named entity 'membrane integrity' named entity 'systematically reviewed' named entity '1.2' named entity 'amino acid' named entity 'cathepsins' named entity 'NSP3' named entity 'protease' named entity 'spike protein' named entity 'amino acid transporter' named entity 'virus' named entity 'protomer' named entity 'dimeric' named entity 'immune response' named entity 'papain' named entity 'PDB' named entity 'SARS-CoV-2' named entity 'host cell' named entity 'ACE2' named entity 'crystal structure' named entity 'highly conserved' named entity 'RCSB' named entity 'membrane integrity' named entity 'protein' named entity 'transcription' named entity 'ACE2' named entity 'RBD' named entity 'proteolytic cleavage' named entity 'ectodomain' named entity 'apilimod' named entity 'SARS-CoV-2' named entity 'RCSB' named entity 'airway' named entity 'cryo EM' named entity 'cell membranes' named entity 'Root mean square deviation' named entity 'RNA' named entity 'protease' named entity 'fusion peptide' named entity 'kinase' named entity 'conserved residues' named entity 'exocytosis' named entity 'amino acid' named entity 'HR2' named entity 'variable domain' named entity 'fusion peptide' named entity 'ACE-2' named entity 'SARS-CoV' named entity 'angstrom' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'SARS-CoV2' named entity 'endocytosis' named entity 'active site' named entity 'RNA-Polymerase' named entity 'SARS-CoV2' named entity 'cell fusion'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software